Research in the Alison Miles Lab focuses on moral distress among pediatric intensive care unit (PICU) clinicians. We have interviewed practitioners involved in the long-term care of patients in the PICU from two months to two years. By identifying the challenges of these cases and what was learned, we hope to develop more effective stress-management strategies for providers. Providers who have less stress are better equipped to care for patients, including those living with chronic diseases. Our team hopes to ultimately improve the field of pediatric palliative care for patients, families and care providers.

Research conducted in the Gary Wand Lab focuses on neuropsychoendocrinology; the neurobiology of substance abuse; physiogenetics and regulation of the stress response; and the relationship between stress and chemical dependency. Current studies seek to better understand the genetic determinants of the stress response and how excessive stress hormone production contributes to neurobiological disorders, including addiction.

Elevation of O-GlcNAc levels modulates numerous pathways in a manner consistent with increased cell survival, including the expression of heat shock proteins. The Zachara Lab's goal is to understand the O-GlcNAc regulated stress response, how this can be manipulated to improve patient outcome and how this response is misregulated in disease.

Research in the David Hager Lab focuses on critical care medicine. Recent studies includes an analysis of advances in the management of the acute respiratory distress syndrome (ARDS) and the development of a targeted real-time early warning score predicting septic shock. Other interests include ventilator-induced lung injury and high-frequency ventilation.

The Outcomes After Critical Illness and Surgery Group is focused on understanding and improving patient outcomes after critical illness and surgery. Research projects include improving long-term outcomes research for acute respiratory distress syndrome/acute respiratory failure (ARDS/ARF) patients; examining the long-term outcomes for acute lung injury/acute respiratory distress syndrome (ALI/ARDS) patients; and evaluating the effects of lower tidal volume ventilation and other aspects of critical illness and ICU care on the long-term physical and mental health outcomes of ALI/ARDS patients.

Research conducted in the Todd Dorman Lab examines the use of informatics in intensive care settings as it relates to remote patient monitoring, safety and management strategies. Specific areas of interest include the surgical stress response; aminoglycoside antibiotics; fungal infections; renal failure; pharmacokinetic models of drug administration; and ICU triage and its impact on disaster preparedness.

The Roy Brower Lab conducts clinical trials related to the management of acute respiratory distress syndrome (ARDS). Our research also involves oxygen toxicity, a potentially fatal condition caused by too much supplemental oxygen.

Dr. Sohn's lab is interested in understanding how biological stress-sensors are assembled, detect danger signals and initiate stress response. Innate immunity is the first line of defense against invading pathogens in higher eukaryotes. We are using in vitro quantitative biochemical assays and mutagenesis and x-ray crystallography to investigate the underlying operating principles of inflammasomes, a component of the innate immune system, to better understand biological stress sensors.

The Franco D’Alessio Lab investigates key topics within the fields of critical care, internal and pulmonary medicine. We primarily explore immunological determinants of acute lung inflammation and repair. Our lab also investigates age-dependent lung immune response in patients with acute lung injury and acute respiratory distress syndrome (ARDS), regulatory T-cells in lung injury and repair, and modulation of alveolar macrophage innate immune response in ARDS.

Research in the Sherita Golden Lab focuses on identifying endocrine risk factors associated with the development of diabetes and cardiovascular disease. We conduct our research by incorporating measures of hormonal function into the design of clinical trials of cardiovascular risk modification, observational studies of incident cardiovascular disease and diabetes, and studies evaluating diabetic complications.